Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Escitalopram (Oral Antidepressant) Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825
View directory record Official record
Conditions
Antidepressant Activity in Healthy Volunteers
Interventions
Escitalopram, Citalopram, Placebo
Drug
Lead sponsor
Michael Henry, MD
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Mechanisms of Antidepressant Non-Response in Late-Life Depression

NCT01931202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo oral tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 1, 2026, 3:02 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216
View directory record Official record
Conditions
Sleep Disorders
Interventions
Zolpidem, Escitalopram, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression-Diabetes Mechanisms: Urban African Americans

NCT00209170
View directory record Official record
Conditions
Diabetes, Depression
Interventions
Beating the Blues, Escitalopram, Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 81 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Predictors of Antidepressant Response

NCT02178696
View directory record Official record
Conditions
Depression
Interventions
Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

NCT00601965
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Early Phase 1 Interventional

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

NCT01725048
View directory record Official record
Conditions
Major Depressive Disorder, Neoplasms
Interventions
Mirtazapine, Citalopram
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 3:02 PM EDT
Terminated Phase 2 Interventional Results available

Adherence to Antidepressant Treatment in Subjects With Depression

NCT03388164
View directory record Official record
Conditions
Depression
Interventions
Escitalopram + RT2CK17, Escitalopram + Placebo
Drug
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Antidepressant Treatment at an Inner City Asthma Clinic

NCT01324700
View directory record Official record
Conditions
Depression, Asthma
Interventions
High severity group: Escitalopram, High severity group: Placebo, Low severity group: Escitalopram, Low severity group: Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 1, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436162
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Antidepressant + Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 3:02 PM EDT